Valuation Black Diamond Therapeutics, Inc.
Stocks
BDTX
US09203E1055
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 21/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.310 USD | -5.76% |
|
-10.88% | -46.09% |
| 11-10 | Black Diamond Therapeutics, Inc. - Special Call | |
| 11-10 | Black Diamond Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
Company Valuation: Black Diamond Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 193.1 | 65.46 | 145.1 | 121.1 | 138.4 | 75.28 | - | - |
| Change | - | -66.1% | 121.66% | -16.54% | 14.33% | -45.62% | - | - |
| Enterprise Value (EV) | -16.69 | -57.35 | 145.1 | 121.1 | 138.4 | 75.28 | 75.28 | 75.28 |
| Change | - | -243.68% | 353.01% | -16.54% | 14.33% | -45.62% | 0% | 0% |
| P/E | -1.54x | -0.71x | -1.49x | -1.69x | 6.23x | -1.87x | -1.4x | -1.42x |
| PBR | 0.98x | - | - | - | - | - | - | - |
| PEG | - | 0x | 0.1x | 0.1x | -0x | 0x | -0x | 1.26x |
| Capitalization / Revenue | - | - | - | - | 1.98x | - | - | - |
| EV / Revenue | - | - | - | - | 0x | - | - | - |
| EV / EBITDA | 0x | 0x | - | -0x | 0x | -1.56x | -1.18x | -0.91x |
| EV / EBIT | 0x | 0x | -0x | -0x | 0x | -1.55x | -1.1x | -0.8x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -2.52 | -1.88 | -1.27 | 0.39 | -0.7012 | -0.9362 | -0.9257 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 70 | - | - | - |
| EBITDA 1 | -126.7 | -92.32 | - | -78.44 | 20.2 | -48.13 | -64.04 | -83.06 |
| EBIT 1 | -126.9 | -92.83 | -86.46 | -78.78 | 19.87 | -48.6 | -68.45 | -94.38 |
| Net income 1 | -125.6 | -91.17 | -82.44 | -69.68 | 22.37 | -41.16 | -64.23 | -90.09 |
| Net Debt | -209.8 | -122.8 | - | - | - | - | - | - |
| Reference price 2 | 5.330 | 1.800 | 2.810 | 2.140 | 2.430 | 1.310 | 1.310 | 1.310 |
| Nbr of stocks (in thousands) | 36,229 | 36,366 | 51,635 | 56,585 | 56,975 | 57,468 | - | - |
| Announcement Date | 3/17/22 A | 3/9/23 A | 3/12/24 A | 3/6/25 A | 3/16/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.87x | - | - | - | 75.28M | ||
| 16.7x | 6.32x | 12.11x | 1.79% | 63.66B | ||
| 31.66x | 8.45x | 27.93x | 0.07% | 58.56B | ||
| 37.7x | 6.72x | 20.09x | 0.86% | 54.19B | ||
| 40.47x | 5.8x | 27.69x | -.--% | 44.66B | ||
| 32.08x | 3.11x | 13.42x | -.--% | 40.51B | ||
| 36.47x | 8.88x | 23.19x | 0.36% | 36.27B | ||
| -19.34x | 51.61x | -20.92x | -.--% | 34.89B | ||
| 41.15x | 7.94x | 26.62x | -.--% | 32.26B | ||
| -87.55x | 16.38x | -94.1x | -.--% | 31.01B | ||
| Average | 12.75x | 12.80x | 4.00x | 0.34% | 40B | |
| Weighted average by Cap. | 18.50x | 11.45x | 8.40x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- BDTX Stock
- Valuation Black Diamond Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















